Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial Required)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to enhance NCIs program for conducting early phase clinical trials in children with cancer, thereby facilitating the introduction of high priority novel agents into the pediatric oncology setting in a timely
manner.
This ability to quickly conduct first in children studies is critical to NCIs overall clinical research program for children with cancer.
The primary scope of the Pediatric Early Phase Clinical Trials Network (PEP-CTN) is to design and conduct pediatric phase 1 trials that will often include phase 2 expansion cohorts.
Conduct of the phase 2 study components within the PEP-CTN is efficient and allows intensive study monitoring for toxicity for these agents undergoing their initial evaluation in children.
When phase 1 testing results for an agent are available, phase 2 studies will also be within the remit of the PEP-CTN.
As well, the PEP-CTN will conduct pilot studies of novel regimens to determine their tolerability so that they can proceed to definitive testing in phase 3 clinical trials.
This ability to quickly conduct first in children studies is critical to NCIs overall clinical research program for children with cancer.
The primary scope of the Pediatric Early Phase Clinical Trials Network (PEP-CTN) is to design and conduct pediatric phase 1 trials that will often include phase 2 expansion cohorts.
Conduct of the phase 2 study components within the PEP-CTN is efficient and allows intensive study monitoring for toxicity for these agents undergoing their initial evaluation in children.
When phase 1 testing results for an agent are available, phase 2 studies will also be within the remit of the PEP-CTN.
As well, the PEP-CTN will conduct pilot studies of novel regimens to determine their tolerability so that they can proceed to definitive testing in phase 3 clinical trials.
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $0
Office: National Institutes of Health
Estimated Funding: $0
Obtain Full Opportunity Text:
https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-007.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-007.html
Contact:
Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Agency Email:
Date Posted:
2023-08-25
Application Due Date:
Archive Date:
2023-12-21
Social Entrepreneurship
Spotlight
Partnerships in Social Enterprises Can Increase Social Impact
Chief executive of HCT, Dai Powell, shares the experiences and practical lessons he learned along the way when teaming up with Ealing Community Transport to deliver site transport during the Olympic Park construction.
Learn How to Identify and Avoid Grant Scams
